BRIOGUT SYRUP contains Saccharomyces boulardii which belongs to the group of medicines called Probiotics. BRIOGUT SYRUP is used to manage acute infectious diarrhoea in children and adolescents (aged below 18 years) which is also used to manage antibiotic associated colitis (inflammatory bowel disease) and diarrhoea.
BRIOGUT SYRUP is also used in addition to vancomycin/metronidazole (antibiotic) medicines to manage recurrent Clostridium difficile diseases (colon infection) and manage tube-feeding associated diarrhoea in affected children. The medicine is also indicated for use in children to manage irritable bowel syndrome (intestinal disorder).
BRIOGUT SYRUP is not recommended for use in children allergic to Saccharomyces boulardii. It is also not recommended for use in children with central venous catheter (long flexible tube inserted into the vein of neck, chest, arm, and/or groin), and in children who are immunocompromised/hospitalised (due to serious illness, and/or altered/weakened immune system).
Before administering BRIOGUT SYRUP, inform your doctor if the child has kidney problems (such as chronic kidney disease), and/or had undergone liver transplantation. BRIOGUT SYRUP is not recommended for use in pregnant and breastfeeding women as it is intended to be used only in children.
BRIOGUT SYRUP should be used with caution in children and adolescents (aged below 18 years) and is advised not to be used in elderly patients as it is intended to be used only in children. Consult your doctor before administering the medicine to the child.
The most common side effects of administering BRIOGUT SYRUP in child are constipation, bloating, and/or faecal incontinence. Consult your doctor if any of these symptoms worsens in child.
No content available
